1,050 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Thursday’s Close
JNJ Johnson & Johnson $139.96 $375.48B Uptrend
Article Searches
Can Smart Beta & Factor ETFs Beat the Market? http://www.zacks.com/stock/news/357973/can-smart-beta-factor-etfs-beat-the-market?cid=CS-ZC-FT-357973 Mar 06, 2019 - Here is what investors need to know about smart beta and factor strategies that combine the best aspects of active and passive investing.
J&J's (JNJ) Nasal Spray Spravato Gets FDA Nod for Depression http://www.zacks.com/stock/news/357836/jjs-jnj-nasal-spray-spravato-gets-fda-nod-for-depression?cid=CS-ZC-FT-357836 Mar 06, 2019 - J&J (JNJ) gets FDA nod for its new nasal spray, Spravato (esketamine) for treatment-resistant depression
The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, JPMorgan, Sun Life and Evergy http://www.zacks.com/stock/news/357595/the-zacks-analyst-blog-highlights-facebook-johnson-johnson-jpmorgan-sun-life-and-evergy?cid=CS-ZC-FT-357595 Mar 04, 2019 - The Zacks Analyst Blog Highlights: Facebook, Johnson & Johnson, JPMorgan, Sun Life and Evergy
The 3 Oldest Members of Biotech's Billion-Burned Club https://www.fool.com/investing/2019/03/03/the-3-oldest-members-of-biotechs-billion-burned-cl.aspx?source=iedfolrf0000001 Mar 03, 2019 - These biopharmaceutical startups have been losing their investors' money for decades.
Top Stock Reports for Facebook, Johnson & Johnson & JPMorgan http://www.zacks.com/research-daily/217355/top-stock-reports-for-facebook-johnson-johnson-jpmorgan?cid=CS-ZC-FT-217355 Mar 01, 2019 - Top Stock Reports for Facebook, Johnson & Johnson & JPMorgan
3 Stocks to Buy Ahead of the Next Market Crash https://www.fool.com/investing/2019/02/28/3-stocks-to-buy-ahead-of-the-next-market-crash.aspx?source=iedfolrf0000001 Feb 28, 2019 - These three titans of their respective industries should be able to weather nearly any market environment.
Big Pharma's Showdown With Congress Over Drug Pricing: What It Really Means for You https://www.fool.com/investing/2019/02/27/big-pharmas-showdown-with-congress-over-drug-prici.aspx?source=iedfolrf0000001 Feb 27, 2019 - A Senate committee roasted top executives of the biggest drugmakers. But will anything change for ordinary Americans?
Theravance (TBPH) Q4 Loss Narrows, Revenues Beat Estimates http://www.zacks.com/stock/news/357180/theravance-tbph-q4-loss-narrows-revenues-beat-estimates?cid=CS-ZC-FT-357180 Feb 27, 2019 - Theravance Biopharma (TBPH) incurs narrower-than-expected loss in Q4. The top line surpasses estimates.
Chardan bullish on MeiraGTx after JNJ investment; shares up 14% https://seekingalpha.com/news/3437840-chardan-bullish-meiragtx-jnj-investment-shares-14-percent?source=feed_news_all Feb 27, 2019 - Chardan Capital Markets reiterates its Buy rating on gene therapy developer MeiraGTx (MGTX +14.4%) with a more bullish price target of $40 (165% upside) (from $30) after it announced a stake by a grou
Congress Grills Drugmakers: 5 Key Takeaways https://www.fool.com/investing/2019/02/26/congress-grills-drugmakers-5-key-takeaways.aspx?source=iedfolrf0000001 Feb 26, 2019 - Top drug companies addressed sky-high drug prices on Capitol Hill today.

Pages: 1234567891011...105

<<<Page 6>